Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient-related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the first MDS core outcome set (MDS-COS) defining a minimum set of outcomes that should be reported in future clinical studies. We performed a comprehensive systematic literature review among MDS studies to extract patient- and/or clinically relevant outcomes. Clinical experts from the European LeukemiaNet MDS (EUMDS) identified 26 potential MDS core outcomes and participated in a three-round Delphi survey. After the first survey (56 experts), 15 outcomes met the inclusion criteria and one additional outcome was included. The second round (38 experts) resulted in six included outcomes. In the third round, a final check on plausibility and practicality of the six included outcomes and their definitions was performed. The final MDS-COS includes: health-related quality of life, treatment-related mortality, overall survival, performance status, safety, and haematological improvement. This newly developed MDS-COS represents the first minimum set of outcomes aiming to enhance comparability across future MDS studies and facilitate a better understanding of treatment effectiveness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
British journal of haematology - 191(2020), 3 vom: 24. Nov., Seite 405-417 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rochau, Ursula [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Completed 22.03.2021 Date Revised 29.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.16654 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309930650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309930650 | ||
| 003 | DE-627 | ||
| 005 | 20231225135007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.16654 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM309930650 | ||
| 035 | |a (NLM)32410281 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rochau, Ursula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2021 | ||
| 500 | |a Date Revised 29.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient-related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the first MDS core outcome set (MDS-COS) defining a minimum set of outcomes that should be reported in future clinical studies. We performed a comprehensive systematic literature review among MDS studies to extract patient- and/or clinically relevant outcomes. Clinical experts from the European LeukemiaNet MDS (EUMDS) identified 26 potential MDS core outcomes and participated in a three-round Delphi survey. After the first survey (56 experts), 15 outcomes met the inclusion criteria and one additional outcome was included. The second round (38 experts) resulted in six included outcomes. In the third round, a final check on plausibility and practicality of the six included outcomes and their definitions was performed. The final MDS-COS includes: health-related quality of life, treatment-related mortality, overall survival, performance status, safety, and haematological improvement. This newly developed MDS-COS represents the first minimum set of outcomes aiming to enhance comparability across future MDS studies and facilitate a better understanding of treatment effectiveness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Delphi survey | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a core outcome set (COS) | |
| 650 | 4 | |a myelodysplastic syndromes (MDS) | |
| 650 | 4 | |a outcome study | |
| 700 | 1 | |a Stojkov, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Conrads-Frank, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Borba, Helena H |e verfasserin |4 aut | |
| 700 | 1 | |a Koinig, Karin A |e verfasserin |4 aut | |
| 700 | 1 | |a Arvandi, Marjan |e verfasserin |4 aut | |
| 700 | 1 | |a van Marrewijk, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a Garelius, Hege |e verfasserin |4 aut | |
| 700 | 1 | |a Germing, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Symeonidis, Argiris |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo F |e verfasserin |4 aut | |
| 700 | 1 | |a Fenaux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a de Witte, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Efficace, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Siebert, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 191(2020), 3 vom: 24. Nov., Seite 405-417 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2020 |g number:3 |g day:24 |g month:11 |g pages:405-417 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.16654 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 191 |j 2020 |e 3 |b 24 |c 11 |h 405-417 | ||